UNASSIGNED: We performed a retrospective observational study of seven patients with ADPKD treated with dapagliflozin at Toranomon Hospital, Tokyo, Japan. We analyzed changes in estimated glomerular filtration rate (eGFR) slope and annual height-corrected total kidney volume before and after starting dapagliflozin treatment.
UNASSIGNED: The median observation period after starting dapagliflozin was 20 months. Four patients received concomitant tolvaptan. The eGFR slope before and after initiation of dapagliflozin could be calculated in six patients and improved in all of them except the one who did not receive a renin-angiotensin system (RAS) inhibitor. Annual height-corrected total kidney volume increased in all patients. Concurrent tolvaptan treatment had no effect.
UNASSIGNED: In CKD patients with ADPKD, dapagliflozin may increase kidney volume but may have a protective effect on kidney function when used concomitantly with RAS inhibitors.
我们进行了一项回顾性观察研究,研究对象为7名在托罗门医院接受达帕格列净治疗的ADPKD患者,东京,日本。我们分析了在开始dapagliflozin治疗前后,估计的肾小球滤过率(eGFR)斜率和年度高度校正的总肾脏体积的变化。
■开始达格列净后的中位观察期为20个月。四名患者同时接受托伐普坦治疗。可以在6例患者中计算dapagliflozin开始之前和之后的eGFR斜率,并且除了未接受肾素-血管紧张素系统(RAS)抑制剂的患者外,所有患者均有所改善。所有患者的年身高校正总肾脏体积均增加。同时托伐普坦治疗没有效果。
■在患有ADPKD的CKD患者中,达格列净可增加肾脏体积,但与RAS抑制剂同时使用时可能对肾功能有保护作用.